YU69000A - Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe - Google Patents

Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe

Info

Publication number
YU69000A
YU69000A YU69000A YU69000A YU69000A YU 69000 A YU69000 A YU 69000A YU 69000 A YU69000 A YU 69000A YU 69000 A YU69000 A YU 69000A YU 69000 A YU69000 A YU 69000A
Authority
YU
Yugoslavia
Prior art keywords
antibodies
derivatives
therapeutic uses
fcεrii
bind
Prior art date
Application number
YU69000A
Other languages
English (en)
Inventor
Jean-Yves Bonnefoy
Scott James Crowe
Jonathan Henry Ellis
Nicholas Timothy Rapson
Jean Shearin
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of YU69000A publication Critical patent/YU69000A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Ovaj pronalazak se odnosi na antitela koja se vezuju na molekul CD23 (FCεRII) tip II, naročito izmenjena antitela koja sadrže antitela koja se vezuju na molekul CD23 (FCεRII) tip II, karakteristična po konstanti afiniteta jednakoj ili većoj od 1x103 (KaMo1-1), dobijanje takvih antitela, farmaceutske formulacije koje sadrže takva antitela i njihovu upotrebu u terapiji posebno u tretmanu autoimunih i inflamatornih poremećaja.[The invention relates to antibodies which bind to the CD23 (FCεRII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FCεRII) type II molecule characterised by an affinity constant equal to or greater than 1x109 Ka Mo1-1, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.
YU69000A 1998-05-09 1999-05-07 Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe YU69000A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody

Publications (1)

Publication Number Publication Date
YU69000A true YU69000A (sh) 2003-08-29

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
YU69000A YU69000A (sh) 1998-05-09 1999-05-07 Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe

Country Status (25)

Country Link
US (1) US7008623B1 (sh)
EP (1) EP1076701A1 (sh)
JP (1) JP2002514421A (sh)
KR (1) KR20010043470A (sh)
CN (1) CN1308676A (sh)
AP (1) AP1547A (sh)
AU (1) AU763491B2 (sh)
BR (1) BR9910327A (sh)
CA (1) CA2328606A1 (sh)
EA (1) EA200001041A1 (sh)
EE (1) EE200000658A (sh)
GB (1) GB9809839D0 (sh)
HR (1) HRP20000762A2 (sh)
HU (1) HUP0102005A3 (sh)
ID (1) ID28088A (sh)
IL (1) IL139384A0 (sh)
IS (1) IS5696A (sh)
NO (1) NO20005632L (sh)
NZ (1) NZ507879A (sh)
PL (1) PL344019A1 (sh)
SK (1) SK16762000A3 (sh)
TR (1) TR200003281T2 (sh)
WO (1) WO1999058679A1 (sh)
YU (1) YU69000A (sh)
ZA (1) ZA200006312B (sh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
AR035352A1 (es) 2000-10-13 2004-05-12 Biogen Inc Anticuerpos anti-lt-beta-r humanizados
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2434668A1 (en) * 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
JP2007521248A (ja) * 2003-12-10 2007-08-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヒト化抗ｃｃｒ２抗体および該抗体を使用する方法
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
US20060246075A1 (en) * 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP3069731A1 (en) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
US20090155255A1 (en) * 2007-09-27 2009-06-18 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
ES2614284T3 (es) 2007-11-30 2017-05-30 Glaxo Group Limited Construcciones de unión a antígenos
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
JP2011522792A (ja) 2008-05-06 2011-08-04 グラクソ グループ リミテッド 生物活性薬の封入
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
WO2010097394A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
JP2012518399A (ja) 2009-02-24 2012-08-16 グラクソ グループ リミテッド 抗原結合性構築物
JP2012522749A (ja) 2009-04-01 2012-09-27 グラクソ グループ リミテッド 抗ｉｌ−２３免疫グロブリン
US20120058116A1 (en) 2009-04-24 2012-03-08 Andrew Beaton Fgfr1c antibody combinations
US8623366B2 (en) 2009-08-28 2014-01-07 Labrys Biologics, Inc. Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
PT2643352T (pt) 2010-11-23 2018-08-01 Glaxo Group Ltd Proteínas de ligação a antigénio para a oncostatina m (osm)
MX2013005847A (es) 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
EP2970464B1 (en) 2013-03-15 2020-05-06 GlaxoSmithKline Intellectual Property Development Limited Anti-lag-3 binding proteins
US9777057B2 (en) * 2013-07-10 2017-10-03 Onconox Aps Antibodies to β2-glycoprotein I and therapeutic uses thereof
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN106456759A (zh) 2014-03-21 2017-02-22 泰华制药国际有限公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
WO2017037203A1 (en) 2015-09-02 2017-03-09 Immutep S.A.S. Anti-LAG-3 Antibodies
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
US10479827B2 (en) * 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
AU2020308053A1 (en) 2019-06-26 2022-01-20 Glaxosmithkline Intellectual Property Development Limited IL1RAP binding proteins
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605442B1 (en) * 1991-07-25 2003-04-16 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
EP1018517A3 (en) * 1994-10-25 2000-07-26 Glaxo Group Limited Binding agents to CD23 for treatment of inflammatory, autoimmune or allergic diseases
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
JP2002514421A (ja) 2002-05-21
TR200003281T2 (tr) 2001-03-21
NZ507879A (en) 2004-02-27
CN1308676A (zh) 2001-08-15
AP1547A (en) 2006-01-13
KR20010043470A (ko) 2001-05-25
PL344019A1 (en) 2001-09-24
GB9809839D0 (en) 1998-07-08
ZA200006312B (en) 2003-02-26
HRP20000762A2 (en) 2001-06-30
SK16762000A3 (sk) 2001-07-10
NO20005632L (no) 2001-01-08
EE200000658A (et) 2002-04-15
HUP0102005A2 (hu) 2001-10-28
HUP0102005A3 (en) 2003-10-28
EA200001041A1 (ru) 2001-06-25
US7008623B1 (en) 2006-03-07
EP1076701A1 (en) 2001-02-21
WO1999058679A1 (en) 1999-11-18
IL139384A0 (en) 2001-11-25
NO20005632D0 (no) 2000-11-08
CA2328606A1 (en) 1999-11-18
ID28088A (id) 2001-05-03
BR9910327A (pt) 2001-01-30
IS5696A (is) 2000-10-31
AP2000001983A0 (en) 2000-12-31
AU3836799A (en) 1999-11-29
AU763491B2 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
YU69000A (sh) Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe
BG109311A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNFAL, AND HIS APPLICATION
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
SI1465626T1 (sl) Farmacevtski sestavki (komplet), ki obsegajo dihidropiridionske spojine in imunoregulacijsko (ali protivnetno) sredstvo, in njihove uporabe
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
ATE427353T1 (de) Heregulin varianten
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
AU2002305450A1 (en) Proteomimetic compounds and methods
EP0797999A3 (en) Formulations of obesity protein
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
DE69911401D1 (en) Immunoregulator
WO2002026781A3 (en) Ige receptor antagonists
AU7525398A (en) Inhibitors for urokinase receptor
ZA965891B (en) Tnf receptor and steroid hormone in a combined therapy
PL321890A1 (en) Variants human dnase i
MX9706429A (es) Variantes de dnasa i humana.
UA83988C2 (ru) Моноклональное антидвойное интегриновое антитело, которое специфически связывает человеческие интегрины альфа v бета 3 и альфа v бета 5, фармацевтическая композиция, которая его содержит, и их применение в терапии